Slide 1: Exchange filing cover letter
Vimla Vimta Labs Limited Registered Office 142, IDA Phase II, Cherlapally Hyderabad-500 051 ,Telangana, India T: +91 4027264141 F : +91 40 2726 3657 Driven by Quality. Inspired by Science. ‘ILL SE 016 2023-24 Date: 03.05.2023 Listing Centre Asst Vice President B S E Limited National Stock Exchange o
Slide 2: Vimta Labs Limited Investor Presentation Q4FY23 & FY23
Vimta Labs Limited Investor Presentation Q4FY23 & FY23 1
Slide 3: Disclaimer
Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i
Slide 4: Contents
Contents Q4 and FY23 Earnings 1 Company Overview 2 Industry Landscape 3 Our Competitive Advantage 4 Way Forward 5 3
Slide 5: Q4 and FY23 Earnings
Q4 and FY23 Earnings ▪ Q4 & FY23 Earnings Highlights ▪ Operational Highlights ▪ Financial Performance: Q4FY23 and FY23 ▪ Key Metrics ▪ Profit & Loss Statement ▪ Balance Sheet 01 4
Slide 6: Q4 & FY23 Highlights
Q4 & FY23 Highlights Q4FY23 Earnings Highlights ➢ Total Income for Q4FY23 grew by 10.7% YoY to Rs. 825 Mn ➢ EBITDA for Q4FY23 is Rs. 242 Mn; EBITDA margins at 29.5% ➢ Q4FY23 PAT is at Rs. 127 Mn up 7.2% YoY ➢ Basic EPS grew by 6.9% to Rs. 5.7 in Q4FY23 against Rs. 5.4 in Q4FY22 FY23 Earnings Highlig
Slide 7: FY23 Operational Highlights
FY23 Operational Highlights Operational Updates Q4FY23 ➢ During the year, the company continued strong growth momentum in food, pharma, and electronics testing/research services with other segments remaining stable. ➢ Inaugurated Electronics and Electrical (E&E) and the entire scope of E&E services
Slide 8: Financial Performance: Q4FY23 and FY23
Financial Performance: Q4FY23 and FY23 Q4FY23 SNAPSHOT Revenue from operations1 (In ₹ Mn) EBIDTA & EBIDTA Margin1 (In ₹ Mn, %) PAT & PAT Margin1 (In ₹ Mn, %) Basic EPS (In ₹) 16% 15% 150 13% 18% 31% 16% 125 5 30% 14% 100 12% 28% 10% 75 8% 10.4% 4.9% 7.2% 50 6% 741 774 818 230 215 242 118 102 127 5.4
Slide 9: Profit & Loss Statement
Profit & Loss Statement Particulars (₹ Mn) Q4 FY23 Q4 FY22 YoY (%) Q3 FY23 QoQ(%) FY23 FY22 YoY (%) Revenue from Operations 818 741 10.4% 774 5.7% 3,182 2,783 14.3% Other Income 7 4 11 34 14 Total Income 825 745 10.7% 785 5.1% 3,216 2,797 15.0% Material and Testing Costs 188 153 173 718 651 Cost of
Slide 10: Balance Sheet
Balance Sheet Particulars (₹ Mn) 31 March 2023 (Audited) 31 March 2022 (Audited) Assets Fixed Assets 1,570 1,498 Capital work-in-progress 123 3 Goodwill 56 56 Intangible assets 122 134 Other non-current assets 116 138 Total non current assets 1,987 1,828 Trade Receivable 800 769 Inventories 226 174
Slide 11: Key Metrics
Key Metrics REVENUE FROM OPERATIONS (₹ Mn) PROFITABILITY (₹ Mn) EBITDA & EBITDA Margin PAT & PAT Margin 31% 30% 29% 30% 10% 15% 15% 4% 15% 33.4% 62.9% 1,807 2,107 2,783 3,182 CAGR 300 530 803 949 CAGR 68 214 413 482 CAGR FY20 FY21 FY22 FY23 FY20 FY21 FY22 FY23 FY20 FY21 FY22 FY23 Total Revenue EBIDT
Slide 12: Shareholding Pattern
Shareholding Pattern Vimta Labs Shareholding as on 31st March 2023 Share Information (as on 31st March 2023) NSE Ticker VIMTALABS BSE Ticker 524394 Market Cap (INR Cr) 695 % free-float 62.8% Others Promoters Free-float market cap (INR Cr) 436 58.4% 37.2% Total Debt (INR Mn) 150 Cash & Cash Equivalen
Slide 13: Company Overview
Company Overview ▪ Vimta Labs at a Glance ▪ Our Journey ▪ Services ▪ Geographical Presence ▪ Management ▪ Accreditation 02 12
Slide 14: Vimta Labs at a Glance
Vimta Labs at a Glance Established in 1984, VIMTA is one of India’s most renowned companies for contract research and testing, recognized for its high quality, cutting edge technology enabled wide spectrum, reliable services and vast experience. The company’s broad capabilities span across biologics
Slide 15: Our Journey
Our Journey ` ` Infrastructure People Investment Capabilities Revenues Pharma & Biopharma: Discovery & 2023 400,000+ ft2 1400+ 492 M development services; Food; 3,216 M Environment; Clinical Diagnostics; Electronics 2015 Analytical – Pharma, Biopharma & 400,000+ ft2 1000+ 580 M Food; Clinical Resear
Slide 16: Our Offerings (1/3)
Our Offerings (1/3) Drug discovery and development support Food & Agriculture Electronics & Environment Testing Services Clinical Diagnostics & Consultancy to Lifesciences Electricals Testing Industry Offerings Pharma Analytical Clinical Research Preclinical Support Industry Pharmaceuticals Pharmace
Slide 17: Our Offerings (2/3)
Our Offerings (2/3) Drug discovery and development support Food & Agriculture Electronics & Environment Testing Electricals Testing Clinical Diagnostics to Lifesciences Services & Consultancy Industry Offerings Food Testing Electronics & Electricals Testing No. of Laboratories 8 1 Accreditations & F
Slide 18: Our Offerings (3/3)
Our Offerings (3/3) Drug discovery and development support Food & Agriculture Electronics & Environment Testing Clinical Diagnostics to Lifesciences Services Electricals Testing & Consultancy Industry Offerings Clinical Diagnostics Environment Testing & Consultancy No. of Laboratories 2 (regional re
Slide 19: Geographical Presence
Geographical Presence Headquartered in Hyderabad, VIMTA has 20 laboratories across India, with a total laboratory space of over 400,000 sq. ft. Hyderabad (Headquarters) Food Clinical Diagnostics Pharma Electronics & Electrical Environment Food Environment Clinical Diagnostics Ahmedabad Coimbatore No
Slide 20: Key Management Team
Key Management Team Harita Vasireddi Sreenivas Neerukonda Harriman Vungal Suresh Kumar Narahari Naidu D.R. Managing Director Executive Director Executive Director - President Chief Financial Officer Operations Harita has close to 25 years of Sreenivas’s core competencies Harriman was inducted to the
Slide 21: Industry Landscape
Industry Landscape ▪ Market Opportunity ▪ Factors Driving Industry Growth 03 20
Slide 22: Markets Opportunity
Markets Opportunity 20 14.6 12.3 (USD bn) 10 7.6 5.4 0.33 0.6 0.27 0.39 0.05 0.1 2022 | 2030 2022 | 2030 2022 | 2030 2022 | 2026 2022 | 2026 2021 | 2028 Pharmaceutical & Preclinical Food Testing Clinical Testing Environment Electronics Testing Biopharmaceutical CAGR:~8% CAGR: 7-8% CAGR:6.2% Testing
Slide 23: Factors Driving Industry Growth
Factors Driving Industry Growth Drug Electrical & Food Environment Discovery & Electronics Diagnostics Testing Testing Development Testing Increasing demand Growing international Surge in demand for Increase in Health risks from for new drug food regulations, certification services regulations to co
Slide 24: Our Competitive Advantage
Our Competitive Advantage ▪ Our Position in the CRTO Landscape ▪ Our Strength 04 23
Slide 25: Our Position in the CRTO Landscape
Our Position in the CRTO Landscape 1 Pharma Analytical & Preclinical 5 Food Testing #1 in India #1 in India Customers – 90% of India top 20 Customers – 70% of India top 10 30% revenues from overseas 2 Clinical Research 6 Environment Among the most reputed CROs in India Among top 5 in India 80% of re
Slide 26: Our Strengths
Our Strengths QUALITY CUSTOMER Long & successful CENTRICITY regulatory track Long term record – cGMP, GLP, partnerships with GCP customers INFRASTRUCTURE KNOWLEDGE Unparalleled lab Multi-disciplinary, infrastructure in the knowledgeable, skilled country. Gold LEED and trained manpower certified Viva
Slide 27: Way Forward
Way Forward ▪ Our Key Growth Drivers & Strategies 05 26
Slide 28: Our Key Growth Drivers & Strategies
Our Key Growth Drivers & Strategies Favourable markets Core business strategies Core operational strategies Best practices ✓ Growth momentum ✓ Capacity expansions ✓ Operational excellence ✓ Good corporate in markets ✓ Service innovations ✓ Hiring right talent governance ✓ Growing demand ✓ Penetratio
Slide 29: Thank You
Thank You May 2023 VIMTA LABS LIMITED INVESTOR RELATIONS AT Registered Office Vimta Labs Ltd. Plot Number 142, IDA Phase 2 Narahai Naidu Dodda, CFO Cherlapally, Hyderabad Narahai.Dodda@vimta.com Telangana, India. 500051 NSE: VIMTALABS, BSE: 524394 ISIN: INE579C01029 Rahul Thakur Advait Bhadekar Webs